I. Transaction Overview
To optimize resource allocation, activate assets, and enhance operational efficiency, Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") held the 23rd meeting of the fourth board of directors and the third extraordinary general meeting of shareholders on February 13, 2026, and March 5, 2026, respectively. The meetings approved the proposal regarding the continued public transfer of the equity of its wholly-owned subsidiary. For specific details, please refer to the announcements disclosed by the Company on February 14, 2026, and March 6, 2026, on the Giant Tide Information Network (http://www.cninfo.com.cn) (Announcement No.: 2026-018, 2026-020).